

CHEMISCREEN™ MEMBRANE PREPARATION RECOMBINANT HUMAN CB₁ CANNABINOID RECEPTOR

CATALOG NUMBER: HTS019M QUANTITY: 200 units
LOT NUMBER: VOLUME/CONCENTRATION 1 mL, 2 mg/mL

BACKGROUND: CB₁ is a GPCR that is expressed primarily in brain and nervous tissue, and mediates numerous CNS responses such as analgesia, appetite, cognition, memory and locomotor activity. A number of cannabinoid ligands bind to CB₁ and activate G_{i/o}-mediated downstream responses, including inhibition of cAMP production and activation of ion channels and MAP kinases. Ligands for CB₁ include exogenous agonists such as Δ⁹-THC, the main psychoactive component of the plant *Cannabis sativa*, and endogenous eicosanoid agonists such as anandamide. A number of synthetic agonists such as CP55940 and R-(+)-WIN55212, and antagonists, such as SR141716A, for CB₁ have been developed (Howlett *et al.*, 2002). CB₁ agonists have clinical utility in analgesia and antiemetic properties, whereas CB₁ antagonists show promise for treatment of appetite in obesity disorders. Millipore's CB₁ membrane preparations are crude membrane preparations made from our proprietary stable recombinant cell lines to ensure high-level of GPCR surface expression; thus, they are ideal HTS tools for screening for agonists and antagonists at CB₁. The membrane preparations exhibit a K_d of 7 nM for [³H]-SR141716A. In the presence of 2 nM [³H]-SR141716A with CP55940 as unlabeled competitor, 10 μg/well CB₁ Membrane Prep yields 4-fold signal-to-background ratio.

APPLICATIONS: Radioligand binding assay and GTPγS binding.




Figure 1. Saturation binding for CB₁. 10 μg/well CB₁ Membrane Preparation was incubated with increasing amount of ³H-labeled SR141716A in the absence (total binding, TB) or presence (nonspecific binding, NSB) of 1000-fold excess unlabeled CP55940. Specific binding (SB) was determined by subtracting NSB from TB.




Figure 2. Competition binding for CB₁. 10 µg/well CB₁ Membrane Preparation (HTS019M) was incubated with 2 nM ³H-labeled SR141716A and increasing concentrations of unlabeled CP55,940, and over 4- fold signal:background was obtained.

Table 1. Signal:background and specific binding obtained with CB₁ membrane preparation

	10 µg
Signal:background	4.7
Specific binding (cpm)	1847




Figure 3. GTPγS binding assay for CB₁. CB₁ Membrane Preparation (HTS019M) at 0.5 units (5 µg) per well and Wild-Type Chem-1 Membrane Preparation (5 µg per well, Millipore cat. # HTS000MC1) was incubated with 0.3 nM [³⁵S]-GTPγS and increasing amounts of unlabeled CP55,940 as described in "[³⁵S]-GTPγS BINDING ASSAY CONDITIONS" below. Bound radioactivity was determined by filtration and scintillation counting.

SPECIFICATIONS: 1 unit=10 μ g
 $B_{\max}$: 15 pmol/mg;
 K_d : 7 nM for SR141716A

Species: Human CB₁ (Accession number X54937)

HOST CELLS: Chem-1, an adherent mammalian cell line without detectable endogenous CB₁ expression.

RECOMMENDED RADIOLIGAND BINDING ASSAY CONDITIONS: Membranes are mixed with radioactive ligand and unlabeled competitor (see Figures 1 and 2 for concentrations tested) in binding buffer in a nonbinding 96-well plate, and incubated for 1-2 h. Prior to filtration, an FC 96-well harvest plate (Millipore cat. # MAHF C1H) is coated with 0.33% polyethyleneimine for 30 min, then washed with 50mM HEPES, pH 7.4, 0.5% BSA. Binding reaction is transferred to the filter plate, and washed 3 times (1 mL per well per wash) with Wash Buffer. The plate is dried and counted.

Binding buffer: 50 mM Hepes, pH 7.4, 5 mM MgCl₂, 1 mM CaCl₂, 0.2% BSA, filtered and stored at 4°C. Ligands were diluted in binding buffer containing 30% DMSO, then added to membranes such that the final DMSO concentration was 15%.

Radioligand: [³H] SR141716A (Amersham #TRK1028)

Wash Buffer: 50 mM Hepes, pH 7.4, 500mM NaCl, 0.1% BSA, filtered and stored at 4°C.

One vial contains enough membranes for at least 200 assays (units), where an unit is the amount of membrane that will yield approximately 4-fold signal:background with [³H] SR141716A at 2 nM

[³⁵S]-GTP γ S BINDING ASSAY CONDITIONS: Membranes are permeabilized by addition of saponin to an equal concentration by mass, then mixed with [³⁵S]-GTP γ S (final concentration of 0.3 nM) in 20 mM HEPES, pH 7.4/100 mM NaCl/10 mM MgCl₂/0.5 μ M GDP in a nonbinding 96-well plate. Unlabeled agonist was added to the final concentration indicated in Figure 1 (final volume 100 μ L), and incubated for 30 min at 30°C. The binding reaction is transferred to an FB filter plate (Millipore MAHF B1H) previously prewetted with water. The plate is washed 3 times (1 mL per well per wash) with cold 10 mM sodium phosphate, pH 7.4, then dried and counted.

PRESENTATION:

Liquid in packaging buffer: 50 mM Tris pH 7.4, 10% glycerol and 1% BSA with no preservatives.

Packaging method: Membrane protein was adjusted to the indicated concentration in packaging buffer, rapidly frozen, and stored at -80°C.

STORAGE/HANDLING:

Store at -70°C. Product is stable for at least 6 months from the date of receipt when stored as directed. Do not freeze and thaw.



REFERENCE: Howlett AC *et al.* (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.* 54: 161-202.

Important Note: *During shipment, small volumes of product will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 μ L or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container's cap.*

FOR RESEARCH USE ONLY; NOT FOR USE IN DIAGNOSTIC
PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

©2006-2012: Millipore Corporation. All rights reserved. No part of these works may be reproduced in any form without permission in writing.